{"id":111062,"date":"2020-08-09T12:22:18","date_gmt":"2020-08-09T19:22:18","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2020\/08\/oxnard-cas-format-medical-research-secures-two-big-clinical-trials-with-regeneron-investigating-regn-cov2"},"modified":"2020-08-09T12:22:18","modified_gmt":"2020-08-09T19:22:18","slug":"oxnard-cas-format-medical-research-secures-two-big-clinical-trials-with-regeneron-investigating-regn-cov2","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2020\/08\/oxnard-cas-format-medical-research-secures-two-big-clinical-trials-with-regeneron-investigating-regn-cov2","title":{"rendered":"Oxnard, CA\u2019s FORMAT Medical Research Secures Two Big Clinical Trials with Regeneron Investigating REGN-COV2"},"content":{"rendered":"

<\/a><\/p>\n

The Study<\/p>\n

Now, Format Medical Research takes on two high profile clinical trials involving the antibody cocktail known as REGN-COV2. Garnering national attention, this investigational therapy targeting COVID-19 has receive a lot of attention. The Ventura County Star reports that the SMO will commence the first study, representing one of 150 sites in North and South America, this Friday. The goal: determine if the antibody medicine offers a safe and effective treatment for those who tested positive for SARS-CoV-2.<\/p>\n

The second study focuses on those participants who are actually healthy but \u201cat risk\u201d of the virus. In this study, the participants will take the therapy to determine if there are prevention properties and the sponsor seeks up to 2,000 participants.<\/p>\n

\n

\nAlthough perhaps not a household name among big pharmaceutical sponsors perhaps that may change as FORMAT Medical Research<\/a> in Oxnard, California, recently secured a major contract with Regeneron to participate in their highly watched, Operation Warp Speed-funded REGN-COV2 double antibody COVID-19 clinical trial. The Southern California-based research organization starts two trials with the New York State-based sponsor chief, Nicholas Focil, who now faces \u201cthe most important study of my career.\u201d<\/em><\/strong><\/p>\n

The SMO<\/strong><\/p>\n

The Oxnard-based research company \u201cfacilities clinical trials.\u201d The \u201cIntegrated Research Organization\u201d also known as a \u201cSite Management Organization\u201d (SMO) was profiled as part of the TrialSite\u2019s <\/em>global SMO survey<\/a> back in early December, 2019. An independent operation, Format Medical Research has aligned with the hyperCORE International, a \u201cSuper Site Network\u201d that purports to standardize systems and processes including business development. With over a decade of experience conducting Phase 1 to 4 clinical trials across a variety of therapeutic areas, they offer SMO and site services for up to 50 sites, SMO employs between 25 and 50 employees. Format claims to have in its network over 10 million patients it can access for studies.<\/p>\n

Continue reading \u201cOxnard, CA\u2019s FORMAT Medical Research Secures Two Big Clinical Trials with Regeneron Investigating REGN-COV2\u201d | ><\/a><\/div><\/p>\n","protected":false},"excerpt":{"rendered":"

The Study Now, Format Medical Research takes on two high profile clinical trials involving the antibody cocktail known as REGN-COV2. Garnering national attention, this investigational therapy targeting COVID-19 has receive a lot of attention. The Ventura County Star reports that the SMO will commence the first study, representing one of 150 sites in North and [\u2026]<\/p>\n","protected":false},"author":534,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11,43],"tags":[],"class_list":["post-111062","post","type-post","status-publish","format-standard","hentry","category-biotech-medical","category-business"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/111062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/534"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=111062"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/111062\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=111062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=111062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=111062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}